CoChat

Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial

Open access
White, Ursula, Fitch, Mark D., Beyl, Robbie A., Hellerstein, Marc K., Ravussin, Eric · 2021 · Diabetologia
Cited by 41

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Aims/hypothesis In vitro and rodent studies suggest that pioglitazone, a thiazolidinedione, can promote adipogenesis in adipose tissue (AT); however, there is a lack of in vivo studies in humans to support these findings. The objectives of this randomised, placebo-controlled, parallel-arm trial were to test if pioglitazone stimulates in vivo adipogenesis in the subcutaneous adipose tissue depots and if these measures were related to metabolic health outcomes in women with obesity. Methods Forty-one healthy women with obesity (20 black; 21 white; 29 ± 6 years; BMI 32.0 ± 1.7 kg/m 2 ; 44.0 ± 3.6% body fat) were randomised to consume 30 mg/day of pioglitazone ( n = 21) or placebo ( n = 20) for 16 weeks. SAS v9.4 was used to generate the block randomisation code sequence (stored in password-protected files) with a 1:1 allocation ratio. The participants and study staff involved in assessing and analysing data outcomes were blinded to the group assignments. The trial was conducted at Pennington Biomedical Research Center and ended in 2016. At baseline and post-intervention, subcutaneous abdominal (scABD) and femoral (scFEM) AT biopsies were collected, and in vivo cellular kinetics (primary endpoint of the trial) were assessed by an 8 week labelling protocol of deuterium ( 2 H) into the DNA of adipose cells. Body composition was measured by dual-energy x-ray absorptiometry (DXA), scABD and visceral AT (VAT) by MRI, ectopic fat by 1 H-MRS, and insulin sensitivity by an OGTT. Results After the 16 week intervention, there was a significant decrease in visceral fat (VAT:total abdominal AT [as a %]; p = 0.002) and an increase in the Matsuda index (i.e. improved insulin sensitivity; p = 0.04) in the pioglitazone group relative to the placebo group. A significant increase in the formation of new adipocytes was observed in the scFEM (Δ = 3.3 ± 1.6%; p = 0.04) but not the scABD depot (Δ = 2.0 ± 2.1%; p = 0.32) in the pioglitazone group relative to the placebo group. No serious adverse events were reported. Conclusions/interpretation Pioglitazone may elicit distinct differences in in vivo adipogenesis in subcutaneous adipose depots in women with obesity, with increased rates in the protective scFEM. Trial registration ClinicalTrials.gov NCT01748994 Funding This study was funded by R01DK090607, P30DK072476, and R03DK112006 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health. The Robert C. and Veronica Atkins Foundation. Graphical abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-020-05281-7

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 35

  1. Saltiel AR, Olefsky JM (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45(12):1661–1669. https://doi.org/10.2337/diab.45.12.1661 · DOI · Paper page
  2. Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164(19):2097–2104. https://doi.org/10.1001/archinte.164.19.2097 · DOI · Paper page
  3. Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316(3):313–324. https://doi.org/10.1001/jama.2016.9400 · DOI · Paper page
  4. Pramyothin P, Karastergiou K (2016) What can we learn from interventions that change fat distribution? Curr Obes Rep 5(2):271–281. https://doi.org/10.1007/s13679-016-0215-x · DOI
  5. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA (2006) Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29(3):510–514. https://doi.org/10.2337/diacare.29.03.06.dc05-2004 · DOI · Paper page
  6. Shadid S, Jensen MD (2003) Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26(11):3148–3152. https://doi.org/10.2337/diacare.26.11.3148 · DOI · Paper page
  7. Sandouk T, Reda D, Hofmann C (1993) Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Phys 264(6 Pt 1):C1600–C1608. https://doi.org/10.1152/ajpcell.1993.264.6.C1600 · DOI · Paper page
  8. Hallakou S, Doare L, Foufelle F et al (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46(9):1393–1399. https://doi.org/10.2337/diab.46.9.1393 · DOI · Paper page
  9. Smith SR, Xie H, Baghian S, Needham A, McNeil M, Bogacka I, Bray GA (2006) Pioglitazone changes the distribution of adipocyte size in type 2 diabetes. Adipocyte 2:11–22
  10. McLaughlin TM, Liu T, Yee G et al (2010) Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity (Silver Spring) 18(5):926–931. https://doi.org/10.1038/oby.2009.380 · DOI · Paper page
  11. Huang T, Qi Q, Zheng Y et al (2015) Genetic predisposition to central obesity and risk of type 2 diabetes: two independent cohort studies. Diabetes Care 38(7):1306–1311. https://doi.org/10.2337/dc14-3084 · DOI
  12. Snijder MB, Visser M, Dekker JM et al (2005) Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia 48(2):301–308. https://doi.org/10.1007/s00125-004-1637-7 · DOI · Paper page
  13. Yim JE, Heshka S, Albu JB, Heymsfield S, Gallagher D (2008) Femoral-gluteal subcutaneous and intermuscular adipose tissues have independent and opposing relationships with CVD risk. J Appl Physiol (1985) 104(3):700–707. https://doi.org/10.1152/japplphysiol.01035.2007 · DOI · Paper page
  14. Snijder MB, Dekker JM, Visser M et al (2004) Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 27(2):372–377. https://doi.org/10.2337/diacare.27.2.372 · DOI · Paper page
  15. Snijder MB, Dekker JM, Visser M et al (2003) Larger thigh and hip circumferences are associated with better glucose tolerance: the Hoorn study. Obes Res 11(1):104–111. https://doi.org/10.1038/oby.2003.18 · DOI · Paper page
  16. Seidell JC, Perusse L, Despres JP, Bouchard C (2001) Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 74(3):315–321. https://doi.org/10.1093/ajcn/74.3.315 · DOI · Paper page
  17. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE (2004) Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 28(3):402–409. https://doi.org/10.1038/sj.ijo.0802567 · DOI · Paper page
  18. Bigaard J, Frederiksen K, Tjonneland A et al (2004) Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? Int J Obes Relat Metab Disord 28(6):741–747. https://doi.org/10.1038/sj.ijo.0802635 · DOI
  19. Tchkonia T, Thomou T, Zhu Y et al (2013) Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 17(5):644–656. https://doi.org/10.1016/j.cmet.2013.03.008 · DOI · Paper page
  20. White UA, Fitch MD, Beyl RA, Hellerstein MK, Ravussin E (2016) Differences in in vivo cellular kinetics in abdominal and femoral subcutaneous adipose tissue in women. Diabetes 65(6):1642–1647. https://doi.org/10.2337/db15-1617 · DOI
  21. White UA, Fitch MD, Beyl RA, Hellerstein MK, Ravussin E (2017) Association of in vivo adipose tissue cellular kinetics with markers of metabolic health in humans. J Clin Endocrinol Metab 102(7):2171–2178. https://doi.org/10.1210/jc.2016-4000 · DOI
  22. White UA, Fitch MD, Beyl RA, Hellerstein MK, Ravussin E (2018) Racial differences in in vivo adipose lipid kinetics in humans. J Lipid Res. https://doi.org/10.1194/jlr.P082628 · DOI
  23. Neese RA, Misell LM, Turner S et al (2002) Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA. Proc Natl Acad Sci U S A 99(24):15345–15350 · DOI · Paper page
  24. Collins ML, Eng S, Hoh R, Hellerstein MK (2003) Measurement of mitochondrial DNA synthesis in vivo using a stable isotope-mass spectrometric technique. J Appl Physiol (1985) 94(6):2203–2211. https://doi.org/10.1152/japplphysiol.00691.2002 · DOI · Paper page
  25. Naressi A, Couturier C, Devos JM et al (2001) Java-based graphical user interface for the MRUI quantitation package. MAGMA 12(2–3):141–152 · DOI · Paper page
  26. Larson-Meyer DE, Newcomer BR, Heilbronn LK et al (2008) Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring) 16(6):1355–1362. https://doi.org/10.1038/oby.2008.201 · DOI · Paper page
  27. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470. https://doi.org/10.2337/diacare.22.9.1462 · DOI · Paper page
  28. Tchoukalova YD, Koutsari C, Karpyak MV, Votruba SB, Wendland E, Jensen MD (2008) Subcutaneous adipocyte size and body fat distribution. Am J Clin Nutr 87(1):56–63. https://doi.org/10.1093/ajcn/87.1.56 · DOI · Paper page
  29. Tchoukalova YD, Fitch M, Rogers PM et al (2012) In vivo adipogenesis in rats measured by cell kinetics in adipocytes and plastic-adherent stroma-vascular cells in response to high-fat diet and thiazolidinedione. Diabetes 61(1):137–144. https://doi.org/10.2337/db10-1768 · DOI
  30. Busch R, Neese RA, Awada M, Hayes GM, Hellerstein MK (2007) Measurement of cell proliferation by heavy water labeling. Nat Protoc 2(12):3045–3057. https://doi.org/10.1038/nprot.2007.420 · DOI · Paper page
  31. Hellerstein MK, Neese RA (1992) Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Phys 263(5 Pt 1):E988–E1001
  32. Boden G, Cheung P, Mozzoli M, Fried SK (2003) Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52(6):753–759. https://doi.org/10.1016/s0026-0495(03)00055-6 · DOI
  33. Kodama N, Tahara N, Tahara A et al (2013) Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. J Clin Endocrinol Metab 98(11):4438–4445. https://doi.org/10.1210/jc.2013-2920 · DOI
  34. Bogacka I, Xie H, Bray GA, Smith SR (2004) The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27(7):1660–1667. https://doi.org/10.2337/diacare.27.7.1660 · DOI · Paper page
  35. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U (2005) Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48(1):96–104. https://doi.org/10.1007/s00125-004-1612-3 · DOI

Cited by

See all 41

Metadata

Authors
White, U., Fitch, M. D., Beyl, R. A., Hellerstein, M. K., & Ravussin, E.
Venue
Diabetologia
Published
2020-10-01
Volume
64
Issue
1
Pages
159-167
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W3091646869
Cited by
41
References
13
FWCI
3.14
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • National Institute of General Medical Sciences (U54 GM104940)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R03DK112006)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-020-05281-7
The paper
White, U., Fitch, M. D., Beyl, R. A., Hellerstein, M. K., & Ravussin, E. (2021). Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-020-05281-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.